Search Results

enGene Holdings Inc. today announced that Jason Hanson, Chief Executive Officer, will present a corporate overview at the Jefferies Global Healthcare Conference in New York City, on June 5, 2024, at 12:30 p.m. ET.

enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”) today announced its financial results for the first quarter ended January 31, 2024.

EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has announced strategic partnerships with Singapore Institute of Advanced Medicine Holdings and Singapore Medical Incorporation.

enGene Holdings Inc., a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer, announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company’s 2024 annual meeting of shareholders.

enGene Holdings Inc. announced that Jason Hanson, Chief Executive Officer, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on March 13, 2024, at 8:40 a.m. ET.

enGene Holdings Inc. (Nasdaq: ENGN) or (“enGene” or the “Company”) today announced an oral presentation at the American Urology Association (AUA) 2024 Annual Meeting being held May 3-6, 2024 in San Antonio, Texas.

enGene Holdings Inc. today announced the appointment of Lee Giguere as Chief Legal Officer and Corporate Secretary.